Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Altria Group, Inc. (MO) — XLP Consumer Staples · S&P 500 Profile |奧馳亞集團介紹

consumer-staplesS&P500xlpxlp-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Altria Group, Inc. (MO) — Business, History & S&P 500 Profile |奧馳亞集團介紹

Altria Group company profile · smokeable & oral tobacco · history · financial snapshot · S&P 500 rank #92 · 奧馳亞集團業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$128.15B
Oct 29, 2026 · Price $76.75 · Frozen benchmark
S&P 500 WEIGHT
0.18%
Rank #92 · Oct 29, 2026 (Slickcharts)
FY2025 NET REVENUES
$23.28B
−3.1% YoY · Net of excise taxes $20.14B
FY2025 NET EARNINGS
$6.95B
Reported diluted EPS $4.12 · Adjusted diluted EPS $5.42

SNAPSHOT

TickerMO (NYSE)
CompanyAltria Group, Inc.
GICS sector / industryConsumer Staples (XLP) / Tobacco
S&P 500 rank (by weight)#92 · 0.18% (Oct 29, 2026)
Sector rank (by market cap)#7 in Consumer Staples (Oct 29, 2026)
HeadquartersRichmond, Virginia
Founded1985 (as Philip Morris Companies Inc., the holding company)
CEOBilly Gifford (since April 2020)
EmployeesNot available
Market cap$128.15B (Oct 29, 2026; price $76.75)
SEC filingsEDGAR — CIK 0000764180

WHAT IT DOES

Altria is America's largest tobacco company, selling cigarettes and cigars through Philip Morris USA and John Middleton, and smokeless tobacco and oral nicotine pouches through U.S. Smokeless Tobacco and Helix. It also holds large equity investments in Anheuser-Busch InBev and Cronos. FY2025 net revenues were $23.28B, down 3.1%, and revenues net of excise taxes were $20.14B.

Smokeable products ($20.49B) still dominate, led by Marlboro, the best-selling US cigarette brand, but the volume trend is structural decline: domestic cigarette shipment volume fell 10.0% in 2025 to 61.8 billion units, as smokers quit, switch or trade to illicit and alternative products. Pricing power — raising prices faster than volumes fall — is what keeps smokeable profit growing despite shrinking units.

Oral tobacco ($2.80B) is the growth bet: Copenhagen and Skoal smokeless products plus on! nicotine pouches, aimed at adult smokers moving away from combustibles. E-vapor (NJOY) took large non-cash impairments in 2025 and was removed as a reportable segment in early 2026, a reminder that the smoke-free transition is expensive and uncertain even for the incumbent.

BUSINESS SEGMENTS — FY2025 REVENUE

SegmentRevenueShareYoY
Smokeable products$20.49B88.0%Not available
Oral tobacco products$2.80B12.0%Not available
All other−$0.01B−0.0%Not available
Total net revenues$23.28B100%−3.1%
Source: Altria FY2025 Form 10-K (filed Feb 25, 2026). All other is the reported total less the two disclosed segment totals.

HISTORY

YearMilestone
1822Philip Morris opens a London tobacco shop, the origin of the Philip Morris name
1919Philip Morris & Co. incorporated in the United States
1954Marlboro relaunched as a filtered cigarette; it becomes the US best-seller
1985Philip Morris Companies Inc. formed as the holding company
2003Philip Morris Companies renamed Altria Group, Inc.
2008Philip Morris International spun off, leaving Altria with the US business
2009Acquires UST Inc., adding Copenhagen and Skoal smokeless brands
2019Invests in JUUL Labs; the stake is later written down substantially
2023Acquires NJOY, entering the e-vapor category
2025E-vapor takes large non-cash impairments; cigarette volume falls 10.0%

COMPETITIVE POSITION

  • Marlboro pricing power — the leading US cigarette brand lets Altria raise prices to offset volume decline, a lever no rival matches at scale.
  • Distribution moat — entrenched retail and wholesale distribution across US convenience and tobacco outlets keeps shelf space hard to displace.
  • Cash returns — the business converts profit into dividends and buybacks; $8B was returned to shareholders in 2025 through dividends and repurchases combined.
  • Smoke-free pivot — on! pouches and the oral portfolio are the credible growth path if combustible volumes keep falling.
  • Competition — Reynolds American (British American Tobacco) and Philip Morris International's US-licensed IQOS on combustibles and heated tobacco, plus illicit trade and vaping rivals.

FINANCIAL SNAPSHOT — FY2025

Net revenues$23.28B (−3.1% YoY)
Revenues net of excise taxes$20.14B (−1.5% YoY)
Net earnings$6.95B
Reported diluted EPS$4.12 (−37.0% YoY, vs a 2024 IQOS-rights gain)
Adjusted diluted EPS$5.42 (+4.4% YoY)
Domestic cigarette volume61.8 billion units (−10.0% YoY)
Oral tobacco shipment volume732.4 million cans (−5.5% YoY)
Source: Altria FY2025 Form 10-K (filed Feb 25, 2026) and Q4/FY2025 results release (Jan 29, 2026). Reported EPS fell mainly on the absence of the 2024 IQOS gain, tax items and e-vapor impairments.

KEY RISKS

  • Volume decline — cigarette volumes fall every year; pricing cannot offset decline forever if elasticity rises or illicit trade grows.
  • Regulation — FDA nicotine limits, flavor rules, menthol bans and excise-tax increases can cut volumes or raise costs abruptly.
  • Smoke-free execution — NJOY impairments show the cost of failed bets; on! must win share against Zyn and other pouches.
  • Litigation — tobacco litigation and settlement costs remain a standing overhang on earnings and cash flow.
  • Equity-investment swings — ABI and Cronos results, reported on a one-quarter lag, add earnings volatility unrelated to tobacco operations.

WHY IT MATTERS FOR THE S&P 500

Altria is the S&P 500's tobacco income play: at a 0.18% index weight and the #7 market cap in Consumer Staples, it is the index's main exposure to US tobacco cash flows, pricing power and the economics of a declining but highly profitable category.

Its volume, pricing and smoke-free mix are read as the real-time state of the US nicotine market — 61.8 billion cigarettes shipped in 2025, down 10.0%, against a growing oral portfolio — and its dividend capacity is a test of how long a shrinking category can fund shareholder returns.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 29, 2026 close)
FinancialsAltria FY2025 Form 10-K (SEC EDGAR, filed Feb 25, 2026; fiscal year ended Dec 31, 2025)
Sector classificationGICS (Tobacco) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Altria

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼MO(NYSE)
公司Altria Group, Inc.
GICS 板塊/行業必需消費品(XLP)/煙草
標普500排名(按權重)#92 · 0.18%(2026 年 10 月 29 日)
板塊內排名(按市值)必需消費品第 #7(2026 年 10 月 29 日)
總部美國弗吉尼亞州里士滿
成立1985 年(原名 Philip Morris Companies Inc.,控股公司)
行政總裁Billy Gifford(自 2020 年 4 月)
員工Not available
市值$128.15B(2026 年 10 月 29 日;價格 $76.75)
SEC 申報EDGAR — CIK 0000764180

業務概覽

奧馳亞是美國最大的煙草公司,經 Philip Morris USA 與 John Middleton 銷售香煙與雪茄,經 U.S. Smokeless Tobacco 與 Helix 銷售無煙煙草與口含尼古丁袋;另持有 Anheuser-Busch InBev 與 Cronos 的大額股權投資。FY2025 淨收入為 $23.28B,下跌 3.1%,扣除消費稅後收入為 $20.14B。

可燃煙草產品($20.49B)仍佔主導,以美國最暢銷香煙品牌 Marlboro 為首,但銷量趨勢是結構性下滑:2025 年國內香煙出貨量下跌 10.0% 至 618 億支,因吸煙者戒煙、轉用或轉向非法與替代產品。定價能力——加價快於銷量下跌——是令可燃利潤在單位萎縮下仍能增長的原因。

口含煙草($2.80B)是增長賭注:Copenhagen 與 Skoal 無煙產品加上 on! 尼古丁袋,瞄準遠離可燃產品的成年吸煙者。電子煙(NJOY)在 2025 年計提大額非現金減值,並於 2026 年初不再列為報告板塊,提醒即使是 incumbent,走向無煙的轉型亦代價高昂且充滿不確定性。

業務板塊 — FY2025 收入

板塊收入佔比同比
可燃煙草產品$20.49B88.0%Not available
口含煙草產品$2.80B12.0%Not available
所有其他−$0.01B−0.0%Not available
淨收入總額$23.28B100%−3.1%
來源:奧馳亞 FY2025 Form 10-K(2026 年 2 月 25 日申報)。所有其他為報告總額減去兩個已披露板塊之數。

歷史沿革

年份里程碑
1822Philip Morris 在倫敦開設煙草店,為 Philip Morris 之名的源頭
1919Philip Morris & Co. 在美國註冊成立
1954Marlboro 以過濾嘴香煙重新推出,後成為美國最暢銷品牌
1985Philip Morris Companies Inc. 成立為控股公司
2003Philip Morris Companies 更名為 Altria Group, Inc.
2008Philip Morris International 分拆,奧馳亞保留美國業務
2009收購 UST Inc.,加入 Copenhagen 與 Skoal 無煙品牌
2019投資 JUUL Labs;該持股其後大幅減值
2023收購 NJOY,進入電子煙品類
2025電子煙計提大額非現金減值;香煙銷量下跌 10.0%

競爭地位

  • Marlboro 定價能力——美國領先香煙品牌令奧馳亞可加價以抵銷銷量下滑,規模上無對手能及。
  • 分銷護城河——深入美國便利店與煙草零售批發的分銷網絡,令貨架位置難以被取代。
  • 現金回報——業務將利潤轉化為股息與回購;2025 年經股息與回購合計向股東返還 $8B。
  • 無煙轉型——on! 口含袋與口含產品組合,是可燃銷量持續下跌下的可信增長路徑。
  • 競爭——Reynolds American(英美煙草)與 Philip Morris International 在美國授權的 IQOS(可燃與加熱煙草),另加非法貿易與電子煙對手。

財務快照 — FY2025

淨收入$23.28B(同比 −3.1%)
扣除消費稅後收入$20.14B(同比 −1.5%)
淨利潤$6.95B
報告攤薄每股盈利$4.12(同比 −37.0%,因 2024 年 IQOS 權利出售收益)
經調整攤薄每股盈利$5.42(同比 +4.4%)
國內香煙銷量618 億支(同比 −10.0%)
口含煙草出貨量7.324 億罐(同比 −5.5%)
來源:奧馳亞 FY2025 Form 10-K(2026 年 2 月 25 日申報)及 2025 年第四季/全年業績發佈(2026 年 1 月 29 日)。報告每股盈利下跌主要因 2024 年 IQOS 收益不再出現、稅項項目與電子煙減值。

主要風險

  • 銷量下滑——香煙銷量年年下跌;若彈性上升或非法貿易增長,加價無法永遠抵銷跌幅。
  • 監管——FDA 尼古丁上限、口味規則、薄荷禁令與消費稅上調,可突然削減銷量或推高成本。
  • 無煙執行——NJOY 減值顯示失敗賭注的代價;on! 須在 Zyn 等口含袋對手中贏得份額。
  • 訴訟——煙草訴訟與和解成本,仍是盈利與現金流的長期陰影。
  • 股權投資波動——ABI 與 Cronos 業績按一季滯後報告,帶來與煙草業務無關的盈利波動。

對標普500的重要性

奧馳亞是標普500的煙草收益標的:指數權重 0.18%、必需消費品板塊市值第 #7,是指數對美國煙草現金流、定價能力,以及一個萎縮但利潤極高品類的經濟學的主要敞口。

其銷量、定價與無煙組合,是美國尼古丁市場的即時狀態——2025 年香煙出貨 618 億支,下跌 10.0%,口含產品組合則在增長——而其派息能力,則考驗一個萎縮品類能為股東回報供資多久。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 29 日收盤)
財務奧馳亞 FY2025 Form 10-K(SEC EDGAR,2026 年 2 月 25 日申報;財政年度截至 2025 年 12 月 31 日)
板塊分類GICS(煙草),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Altria

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · MO
Data as of Oct 29, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Starbucks Corporation (SBUX) — XLY Consumer Discretionary · S&P 500 Profile |星巴克介紹Next · The Progressive Corporation (PGR) — XLF Financials · S&P 500 Profile |前進保險公司介紹

Entered 2026-10-30 05:05 · updated 2026-11-14 23:30 · rev 7